Medtronic’s stent is intended to provide an off-the-shelf endovascular solution for treating thoracoabdominal aortic aneurysm. Credit: Medtronic plc.

Medical device producer Medtronic has secured Breakthrough Device designation from the US Food and Drug Administration (FDA) for its implantable Left Ventricular Assist Device (LVAD) for patients suffering from advanced heart failure.

LVAD systems include an implanted heart pump to raise the amount of blood circulating the body.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The pump is linked to a driveline cable, extending outside the body to a controller, then connected to power sources (AC or DC adapter, batteries).

The future system is designed to be fully implanted within the body.

The FDA Breakthrough Device Programme is designed to help patients receive access to breakthrough technologies that come with the potential to offer more effective treatment or diagnosis for life-threatening or debilitating diseases.

Under the programme, the FDA will offer Medtronic with priority review and interactive communication concerning device development and clinical trial protocols, through to commercialisation decisions.

The Medtronic Fully Implantable LVAD is currently in early stage research and development and is not available for sale anywhere in the world.

Medtronic provides a range of medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias.

Earlier this month, the US FDA granted breakthrough device designation to Medtronic’s minimally invasive Valiant TAAA Stent Graft System.

Valiant TAAA Stent Graft System is designed to repair a thoracoabdominal aortic aneurysm (TAAA). A TAAA causes swelling of the aorta, extending from the chest into the abdomen.

Commonly, TAAA impacts the branch arteries supplying blood to several internal organs. The condition accounts for approximately 15% of all thoracic aneurysms.